ASeq Newsletter

ASeq Newsletter

Share this post

ASeq Newsletter
ASeq Newsletter
Sequencing In Oncology

Sequencing In Oncology

Jan 23, 2024
∙ Paid
5

Share this post

ASeq Newsletter
ASeq Newsletter
Sequencing In Oncology
Share

Yesterday I looked briefly at clinical sequencing markets. We saw that clinical is now overtaking research in sequencing. And we also saw that oncology was the largest clinical market, accounting for ~$1B of Illumina’s revenue.

Today I wanted to try and break this down a little further. I looked at a few oncology companies (Exact, Guardant and Myriad).

Not Exact…

Of these Exact Sciences appears to be the biggest, taking in ~$2.5B in revenue. They break this down between screening and precision oncology:

In screening Cologuard seems likely to be Exact’s most popular test. This is a methylation based Colon cancer screening test. However from this uses a qPCR readout of a small number of biomarkers. So not so interesting for us…

Exact’s precision oncology tests also appear to be qPCR based (OncoType Dx). OncoDetect, oncoExTra are sequencing based, but these were only launched in 2023 and I don’t think have gained widespread adoption.

Overall… doesn’t seem like Exact is sending much cash Illumina’s way.

Guardant

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Nava Whiteford
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share